Ling Dandan, Jia Xueli, Wang Ke, Yan Qiucheng, Yuan Bochuan, Du Lina, Li Miao, Jin Yiguang
Anhui Medical University, Hefei 230032, China.
Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Acta Pharm Sin B. 2024 Jan;14(1):365-377. doi: 10.1016/j.apsb.2023.08.012. Epub 2023 Aug 19.
Chemotherapy is one of the major approaches for the treatment of metastatic lung cancer, although it is limited by the low tumor delivery efficacy of anticancer drugs. Bacterial therapy is emerging for cancer treatment due to its high immune stimulation effect; however, excessively generated immunogenicity will cause serious inflammatory response syndrome. Here, we prepared cancer cell membrane-coated liposomal paclitaxel-loaded bacterial ghosts (LP@BG@CCM) by layer-by-layer encapsulation for the treatment of metastatic lung cancer. The preparation processes were simple, only involving film formation, electroporation, and pore extrusion. LP@BG@CCM owned much higher 4T1 cancer cell toxicity than LP@BG due to its faster fusion with cancer cells. In the 4T1 breast cancer metastatic lung cancer mouse models, the remarkably higher lung targeting of intravenously injected LP@BG@CCM was observed with the almost normalized lung appearance, the reduced lung weight, the clear lung tissue structure, and the enhanced cancer cell apoptosis compared to its precursors. Moreover, several major immune factors were improved after administration of LP@BG@CCM, including the CD4/CD8a T cells in the spleen and the TNF-, IFN-, and IL-4 in the lung. LP@BG@CCM exhibits the optimal synergistic chemo-immunotherapy, which is a promising medication for the treatment of metastatic lung cancer.
化疗是转移性肺癌治疗的主要方法之一,尽管其受抗癌药物肿瘤递送效率低的限制。细菌疗法因其高免疫刺激作用而在癌症治疗中崭露头角;然而,过度产生的免疫原性会导致严重的炎症反应综合征。在此,我们通过逐层包封制备了癌细胞膜包被的载紫杉醇细菌幽灵(LP@BG@CCM)用于转移性肺癌的治疗。制备过程简单,仅涉及成膜、电穿孔和孔径挤压。LP@BG@CCM 由于其与癌细胞的融合更快,对 4T1 癌细胞的毒性比 LP@BG 高得多。在 4T1 乳腺癌转移性肺癌小鼠模型中,与之前的制剂相比,静脉注射 LP@BG@CCM 具有显著更高的肺靶向性,表现为肺外观几乎正常化、肺重量减轻、肺组织结构清晰以及癌细胞凋亡增强。此外,给予 LP@BG@CCM 后,包括脾脏中的 CD4/CD8a T 细胞以及肺中的 TNF-、IFN-和 IL-4 在内的几种主要免疫因子得到改善。LP@BG@CCM 展现出最佳的协同化学免疫疗法,是一种有前途的转移性肺癌治疗药物。